Biofilm Susceptibility Testing in the Clinical Laboratory

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Biofilm susceptibility testing addresses the gap between conventional planktonic antimicrobial susceptibility testing and clinical outcomes in chronic infections, but no official agency has yet standardized procedures, parameters, or breakpoints for routine laboratory implementation.
• Laboratory directors should evaluate clinical demand, regulatory approval pathways, cost, and technical expertise before selecting among microtiter plate assays, the Calgary device, substratum suspending reactors, flow cells, or newer microfluidic platforms.
• Results from biofilm susceptibility testing currently inform research and specialized clinical consultations instead of routine reporting, and interpreting them requires understanding that biofilm pharmacodynamic parameters differ substantially from conventional minimum inhibitory concentration values.

The Clinical Problem That Biofilm Susceptibility Testing Addresses

Biofilms are organized bacterial communities embedded in an extracellular polymeric matrix that attach to living or abiotic surfaces. The development of biofilms is currently recognized as one of the most relevant drivers of persistent infections. Among these, chronic respiratory infection by Pseudomonas aeruginosa in cystic fibrosis patients is probably the most intensively studied example. The lack of correlation between conventional susceptibility test results and therapeutic success in chronic infections is probably a consequence of using planktonically growing instead of biofilm-growing bacteria in standard testing.

Conventional antimicrobial susceptibility testing methods, including broth microdilution and disk diffusion, measure the activity of antibiotics against bacteria in their free-swimming planktonic state. These methods form the basis of clinical decision-making for acute infections and are standardized by organizations such as the Clinical and Laboratory Standards Institute. However, when bacteria adopt a biofilm lifestyle, their physiology changes dramatically. Cells within a biofilm exhibit reduced metabolic activity, differential gene expression, and physical protection from antimicrobial agents by the extracellular polymeric matrix. These changes can produce substantial quantitative and qualitative differences in antibiotic effects when comparing planktonic and biofilm bacteria.

The global context of antimicrobial resistance adds urgency to this problem. The World Health Organization identifies antimicrobial resistance as a threat to modern medicine, and biofilm-associated infections compound this challenge because they are difficult to eradicate with conventional antibiotic regimens. Chronic infections such as prosthetic joint infections, catheter-associated urinary tract infections, endocarditis, and chronic wound infections frequently involve biofilms and often require prolonged or combination therapy, surgical intervention, or device removal.

For clinical laboratory directors, the question is whether their laboratory should invest in biofilm susceptibility testing, which method to adopt, and how to interpret and report results that lack official standardization. This article provides a decision framework for that evaluation.

Understanding Biofilm Physiology and Antimicrobial Resistance Mechanisms

The Biofilm Lifecycle and Its Relevance to Susceptibility Testing

Biofilm formation proceeds through distinct stages that have direct implications for susceptibility testing. Initially, planktonic bacteria attach reversibly to a surface. This attachment becomes irreversible as cells produce extracellular polymeric substances. The biofilm then matures through microcolony formation and the development of a three-dimensional structure with channels that facilitate nutrient and waste exchange. Finally, cells can detach from the mature biofilm and disseminate to establish new sites of infection.

The extracellular polymeric matrix is not an inert barrier. It contains polysaccharides, proteins, extracellular DNA, and lipids that can bind or sequester antimicrobial agents. The matrix also contributes to the establishment of chemical gradients within the biofilm, creating microenvironments with varying oxygen tension, pH, and nutrient availability. Cells in different regions of the biofilm may be actively growing, slowly growing, or in a dormant state, and these physiological differences influence their susceptibility to antibiotics that target active cellular processes.

Mechanisms of Reduced Antimicrobial Susceptibility in Biofilms

Several mechanisms contribute to the reduced susceptibility of biofilm bacteria compared with their planktonic counterparts. These mechanisms are not mutually exclusive and often act in concert.

The matrix itself can act as a diffusion barrier, slowing the penetration of some antimicrobial agents. However, research has shown that many antibiotics do penetrate biofilms, so reduced penetration alone does not fully explain the observed tolerance. The physiological heterogeneity of cells within the biofilm is a more significant factor. Antibiotics that require active cell growth, such as beta-lactams, are less effective against slowly growing or dormant cells in the deeper layers of the biofilm.

Persister cells represent a subpopulation of bacteria that are metabolically quiescent and tolerant to antibiotics without having acquired genetic resistance. These cells can survive antibiotic exposure and repopulate the biofilm once treatment stops. This phenomenon helps explain why biofilm infections often recur after apparently successful treatment.

Biofilm growth also induces changes in gene expression that can contribute to reduced susceptibility. Cells in biofilms may upregulate efflux pumps, alter porin expression, or modify their cell envelope in ways that reduce antibiotic accumulation. Additionally, the high cell density within biofilms facilitates horizontal gene transfer, which can spread resistance genes within the community.

Distinguishing Tolerance from Resistance

A critical distinction for laboratory professionals is the difference between antimicrobial resistance and antimicrobial tolerance. Resistance is a heritable genetic trait that increases the minimum inhibitory concentration of an antibiotic and can be detected by conventional susceptibility testing. Tolerance is a non-heritable physiological state in which bacteria survive antibiotic exposure without an increase in the minimum inhibitory concentration. Biofilm bacteria are often tolerant instead of resistant, which means that conventional susceptibility testing may report the organism as susceptible while the biofilm infection fails to respond to treatment.

This distinction has important implications for testing and reporting. A biofilm susceptibility result that differs from the conventional result does not necessarily indicate that the organism has acquired new resistance mechanisms. It may reflect the physiological state of the bacteria within the biofilm. Laboratory directors and clinicians must understand this distinction to interpret biofilm susceptibility results appropriately.

Conventional Antimicrobial Susceptibility Testing and Its Limitations

The Role of Standardized Planktonic Testing

Conventional antimicrobial susceptibility testing remains the foundation of clinical microbiology practice. The Clinical and Laboratory Standards Institute publishes standards for susceptibility testing methods, quality control, and interpretive criteria. These standards ensure that results are reproducible across laboratories and that breakpoints reflect current clinical and microbiological data.

The minimum inhibitory concentration is the lowest concentration of an antibiotic that inhibits visible growth of a microorganism under standardized conditions. This parameter is used to categorize organisms as susceptible, intermediate, or resistant based on clinical breakpoints. For acute infections caused by planktonic bacteria, this approach has proven utility and remains the standard of care.

Why Conventional Testing Fails for Biofilm Infections

The limitation of conventional testing for biofilm infections lies in its fundamental assumption that the bacteria being tested are in a planktonic state. When a chronic infection involves biofilm-growing bacteria, the conventional susceptibility result may not predict therapeutic outcome. Studies of biofilm-growing bacteria demonstrate very significant quantitative and qualitative differences for the effects of most antibiotics when acting on planktonic or biofilm bacteria, as reported in clinical microbiology research.

For example, an antibiotic that appears highly active against planktonic Pseudomonas aeruginosa may show markedly reduced activity against the same organism growing as a biofilm. The minimum biofilm inhibitory concentration and the minimum biofilm eradication concentration are often substantially higher than the conventional minimum inhibitory concentration. In some cases, antibiotics that are bactericidal against planktonic cells may be only bacteriostatic or ineffective against biofilm cells.

This disconnect between laboratory results and clinical outcomes creates a dilemma for clinicians managing chronic infections. They may select antibiotics based on conventional susceptibility testing only to observe treatment failure. Biofilm susceptibility testing aims to provide more clinically relevant information by measuring antibiotic activity against bacteria in their biofilm state.

The Gap in Official Standardization

Despite the clinical rationale for biofilm susceptibility testing, official agencies have not yet standardized the procedures, parameters, and breakpoints needed for implementation in clinical microbiology laboratories for routine susceptibility testing, according to published research on biofilm susceptibility testing. This lack of standardization is a major consideration for laboratory directors evaluating whether to offer biofilm susceptibility testing.

Without official standards, laboratories cannot validate their methods against reference procedures, establish quality control ranges, or report results using interpretive breakpoints that have regulatory approval. Results from biofilm susceptibility testing must therefore be interpreted with caution and communicated to clinicians as investigational or research-use information instead of as standard clinical results.

In Vitro Biofilm Models for Susceptibility Testing

Microtiter Plate-Based Assays

Microtiter plate-based assays are among the most widely used in vitro biofilm models for susceptibility studies, as documented in clinical microbiology literature. These assays typically involve growing biofilms in the wells of a 96-well microtiter plate, exposing the biofilms to serial dilutions of antibiotics, and then measuring the viability or biomass of the remaining biofilm.

The crystal violet staining method is commonly used to quantify biofilm biomass. After antibiotic exposure, the wells are washed to remove planktonic cells, the remaining biofilm is stained with crystal violet, and the dye is solubilized for spectrophotometric measurement. This method is simple, inexpensive, and amenable to high-throughput screening.

For viability assessment, the minimum biofilm eradication concentration can be determined by exposing mature biofilms to antibiotics and then subculturing the surviving cells to determine the lowest concentration that eradicates the biofilm. Alternatively, metabolic assays using tetrazolium salts such as MTT or XTT can measure the metabolic activity of cells within the biofilm.

The advantages of microtiter plate assays include their low cost, ease of use, and compatibility with standard laboratory equipment. However, they have limitations. The static nature of the system does not replicate the fluid dynamics of many in vivo biofilm environments. The biofilms that form in microtiter plates may differ in structure and physiology from those that form under flow conditions. Additionally, the washing steps required to remove planktonic cells can also remove loosely attached biofilm cells, potentially affecting the accuracy of the results.

The Calgary Biofilm Device

The Calgary biofilm device, also known as the MBEC assay, is a specialized microtiter plate system designed for biofilm susceptibility testing, as described in published research on in vitro biofilm models. The device consists of a lid with 96 pegs that fit into a standard microtiter plate. Biofilms grow on the pegs, which can then be transferred to a new plate containing antibiotic dilutions for exposure.

After antibiotic exposure, the pegs are rinsed to remove planktonic cells, and the surviving biofilm cells are recovered by sonication or other mechanical disruption. The recovered cells are then subcultured to determine the minimum biofilm eradication concentration.

The Calgary device offers several advantages over simple microtiter plate assays. The peg design provides a consistent surface for biofilm formation, and the ability to transfer the pegs between plates facilitates the exposure and recovery steps. The device has been used extensively in biofilm research and has contributed to the understanding of biofilm susceptibility patterns.

However, the Calgary device also has limitations. The static growth conditions do not fully replicate the shear forces and nutrient flow of in vivo biofilms. The recovery step may not remove all biofilm cells from the pegs, potentially underestimating the surviving population. The device is also more expensive than simple microtiter plate assays.

Substratum Suspending Reactors

Substratum suspending reactors are dynamic systems that provide continuous flow and controlled shear conditions for biofilm growth, as noted in clinical microbiology research on biofilm models. These reactors contain substrata on which biofilms form, and the flow of growth medium can be adjusted to mimic different environmental conditions.

The rotating disk reactor and the constant depth film fermenter are examples of substratum suspending reactors used in biofilm research. These systems allow for the growth of biofilms under controlled hydrodynamic conditions and can be used to evaluate the efficacy of antibiotics and disinfectants against mature biofilms.

The advantages of substratum suspending reactors include their ability to produce biofilms that more closely resemble those found in natural and clinical environments. The continuous flow provides a constant supply of nutrients and removes waste products, supporting the growth of thicker and more structurally complex biofilms.

The limitations of these systems include their complexity, cost, and the technical expertise required to operate them. They are not well suited for high-throughput susceptibility testing, and the recovery of biofilm cells for quantitative analysis can be challenging.

Flow Cell Systems

Flow cell systems are another dynamic model for biofilm susceptibility testing, as documented in published research on biofilm susceptibility testing methods. These systems consist of a chamber through which growth medium flows continuously, with a viewing window that allows direct observation of biofilm development using microscopy.

Flow cells are particularly valuable for studying biofilm structure and dynamics in real time. They can be used with confocal laser scanning microscopy to visualize the three-dimensional architecture of biofilms, the distribution of viable and non-viable cells, and the penetration of fluorescently labeled antibiotics.

For susceptibility testing, flow cells can be used to expose biofilms to antibiotics under continuous flow conditions and to monitor the response over time. This approach provides information about the kinetics of antibiotic action against biofilms that is not available from static assays.

The limitations of flow cell systems include their complexity, the need for specialized microscopy equipment, and the difficulty of performing quantitative susceptibility testing. Flow cells are better suited for research applications than for routine clinical laboratory testing.

Microfluidic Platforms and the BiofilmChip

Recent advances in microfluidic technology have led to the development of new devices for biofilm susceptibility testing. The BiofilmChip is a microfluidic platform with an integrated interdigitated sensor that allows for the irreversible and homogeneous attachment of bacterial cells of clinical origin, even directly from clinical specimens, as reported in NPJ Biofilms and Microbiomes research.

The BiofilmChip allows biofilms to be monitored by confocal microscopy or electrical impedance spectroscopy. This real-time monitoring capability distinguishes it from endpoint assays that require destructive sampling. The device can measure the effect of antimicrobials on biofilms without introducing disturbances due to manipulation, thus better mimicking real-life clinical situations.

The BiofilmChip has proven suitable for studying polymicrobial communities, which is relevant because many clinical biofilms involve multiple species. The device is described as a straightforward tool for antimicrobial biofilm susceptibility testing that could be easily implemented in routine clinical laboratories.

The potential advantages of microfluidic platforms include their ability to work with small sample volumes, their compatibility with clinical specimens, and their capacity for real-time monitoring. However, these devices are relatively new, and their performance compared with established methods requires further evaluation. The cost of the devices and the need for specialized equipment may also be considerations for clinical laboratories.

Pharmacodynamic Parameters for Biofilm Susceptibility Testing

Minimum Biofilm Inhibitory Concentration

The minimum biofilm inhibitory concentration is the lowest concentration of an antibiotic that inhibits visible growth of a biofilm, as defined in clinical microbiology research. This parameter is analogous to the conventional minimum inhibitory concentration but is measured against biofilm-growing bacteria.

The minimum biofilm inhibitory concentration can be determined using microtiter plate assays or the Calgary device. Biofilms are grown in the test system, exposed to serial dilutions of the antibiotic, and the lowest concentration that prevents visible biofilm growth is recorded.

The minimum biofilm inhibitory concentration is typically higher than the conventional minimum inhibitory concentration for the same organism and antibiotic. This difference reflects the reduced susceptibility of biofilm cells and provides a more conservative estimate of the antibiotic concentration needed to inhibit bacterial growth in a biofilm-associated infection.

Minimum Biofilm Eradication Concentration

The minimum biofilm eradication concentration is the lowest concentration of an antibiotic that eradicates a preformed biofilm, as described in published research on biofilm pharmacodynamic parameters. This parameter is measured by growing mature biofilms, exposing them to serial dilutions of the antibiotic, and then determining the lowest concentration that kills all cells within the biofilm.

The minimum biofilm eradication concentration is determined by recovering surviving cells from the biofilm after antibiotic exposure and subculturing them to assess viability. The Calgary device is well suited for this determination because the pegs can be transferred to recovery plates after antibiotic exposure.

The minimum biofilm eradication concentration is often substantially higher than the minimum biofilm inhibitory concentration and the conventional minimum inhibitory concentration. This parameter is clinically relevant because it reflects the antibiotic concentration needed to eliminate an established biofilm, which is the goal of treatment for chronic biofilm infections.

Biofilm Bactericidal Concentration

The biofilm bactericidal concentration is the lowest concentration of an antibiotic that achieves a defined reduction in the number of viable cells within a biofilm, typically a 3-log or 99.9% reduction, as noted in clinical microbiology literature on biofilm testing. This parameter is analogous to the minimum bactericidal concentration used for planktonic bacteria.

The biofilm bactericidal concentration is determined by exposing biofilms to serial dilutions of the antibiotic and then quantifying the number of surviving cells. The lowest concentration that achieves the defined reduction in viability is recorded as the biofilm bactericidal concentration.

This parameter provides information about the bactericidal activity of an antibiotic against biofilm cells, which is important for infections where eradication of the biofilm is the therapeutic goal.

Biofilm Prevention Concentration

The biofilm prevention concentration is the lowest concentration of an antibiotic that prevents biofilm formation, as documented in published research on biofilm susceptibility parameters. This parameter is measured by exposing planktonic bacteria to serial dilutions of the antibiotic in a system that supports biofilm formation and determining the lowest concentration that prevents the development of a biofilm.

The biofilm prevention concentration is relevant for prophylaxis, such as preventing biofilm formation on medical devices or preventing infection in patients at high risk for biofilm-associated infections.

The relationship between the biofilm prevention concentration and the conventional minimum inhibitory concentration varies by organism and antibiotic. In some cases, concentrations below the minimum inhibitory concentration may prevent biofilm formation, while in other cases, higher concentrations are required.

Implementing Biofilm Susceptibility Testing in the Clinical Laboratory

Step 1: Assess Clinical Demand and Utility

The first consideration for a laboratory director is whether biofilm susceptibility testing would meaningfully improve patient care in their clinical setting. This assessment requires understanding the patient populations served by the laboratory and the types of infections that are commonly encountered.

Laboratories serving cystic fibrosis centers, orthopedic surgery programs, or infectious disease services that manage chronic device-associated infections may receive more requests for biofilm susceptibility testing. Clinicians managing patients with chronic infections that have failed conventional therapy may seek biofilm susceptibility results to guide alternative treatment strategies.

The laboratory director should consult with clinical stakeholders to understand their needs and expectations. This consultation should include a discussion of the limitations of biofilm susceptibility testing, including the lack of standardized breakpoints and the uncertainty about how results should be interpreted.

Step 2: Evaluate Regulatory and Accreditation Requirements

Clinical laboratories in the United States operate under regulations that govern the validation and use of laboratory-developed tests. Biofilm susceptibility testing methods that are not cleared or approved by regulatory agencies must be validated by the laboratory before they are used for clinical testing.

The laboratory director must determine whether the proposed biofilm susceptibility testing method meets the requirements for a laboratory-developed test under applicable regulations. This determination involves assessing the analytical validity of the method, including its accuracy, precision, and reproducibility.

Accreditation bodies may have specific requirements for laboratory-developed tests, including documentation of validation studies, quality control procedures, and personnel qualifications. The laboratory director should review these requirements before implementing biofilm susceptibility testing.

Step 3: Determine Technical Expertise and Resources

Biofilm susceptibility testing requires technical expertise that may not be present in all clinical microbiology laboratories. The laboratory must have personnel who understand biofilm biology, are trained in the selected testing method, and can troubleshoot technical problems.

The selected method will determine the equipment and supplies needed. Microtiter plate assays require a plate reader, while the Calgary device requires the specialized peg lid system and sonication equipment. Flow cell systems require microscopy equipment and fluidics expertise. Microfluidic platforms require the specific device and associated instrumentation.

The laboratory director should assess whether the existing laboratory infrastructure can support the selected method or whether additional capital investment is required. The ongoing costs of consumables, quality control materials, and personnel time must also be considered.

Step 4: Select the Testing Method

The selection of a biofilm susceptibility testing method should be based on the clinical questions to be answered, the available resources, and the technical expertise of the laboratory staff. The table below summarizes the characteristics of the major biofilm susceptibility testing methods.

For a laboratory seeking to implement biofilm susceptibility testing with minimal investment, a microtiter plate assay or the Calgary device may be the most practical choice. These methods are relatively simple, use equipment that is commonly available in clinical microbiology laboratories, and can process multiple isolates simultaneously.

For a laboratory with research capabilities and a need for more physiologically relevant biofilm models, a flow cell system or substratum suspending reactor may be appropriate. These methods provide more realistic growth conditions but require greater technical expertise and are not well suited for high-throughput testing.

For a laboratory interested in the newest technology and the ability to test clinical specimens directly, a microfluidic platform such as the BiofilmChip may be worth evaluating. These devices offer the potential for real-time monitoring and direct testing of clinical specimens, but their performance characteristics require further validation.

Step 5: Validate the Method

Validation is a critical step in implementing any laboratory-developed test. The laboratory must demonstrate that the biofilm susceptibility testing method produces accurate, precise, and reproducible results.

Validation studies should include assessments of accuracy, precision, reproducibility, and reportable range. The laboratory should test a panel of well-characterized organisms, including reference strains from authenticated culture collections such as the American Type Culture Collection, to establish the performance characteristics of the method.

The validation should also include an assessment of the method's limitations, including its ability to detect clinically relevant differences in biofilm susceptibility and its susceptibility to technical artifacts.

Step 6: Establish Quality Control Procedures

Quality control is essential for ensuring the reliability of biofilm susceptibility testing results. The laboratory must establish procedures for monitoring the performance of the method, including the use of quality control organisms with known biofilm susceptibility characteristics.

Quality control should include assessment of biofilm formation, antibiotic preparation, and endpoint determination. The laboratory should establish acceptable ranges for quality control results and take corrective action when results fall outside these ranges.

The laboratory should also participate in external quality assessment programs if available. These programs provide an independent assessment of the laboratory's performance and can identify problems that might not be apparent from internal quality control alone.

Step 7: Develop Reporting and Interpretation Guidelines

The reporting of biofilm susceptibility testing results requires careful consideration because no standardized interpretive breakpoints exist. The laboratory must develop reporting guidelines that communicate the results clearly while avoiding overinterpretation.

The report should include the testing method used, the pharmacodynamic parameters measured, and the results for each antibiotic tested. The report should also include a statement that interpretive breakpoints for biofilm susceptibility testing have not been established and that results should be interpreted in the context of the patient's clinical situation.

The laboratory should work with clinical stakeholders to develop guidance for interpreting biofilm susceptibility results. This guidance should address the relationship between biofilm susceptibility results and conventional susceptibility results and the implications for treatment decisions.

Step 8: Monitor Performance and Outcomes

After implementing biofilm susceptibility testing, the laboratory should monitor the performance of the method and the clinical utility of the results. This monitoring should include tracking of quality control results, turnaround times, and clinician satisfaction.

The laboratory should also track clinical outcomes, when possible, to assess whether biofilm susceptibility testing results are associated with improved treatment outcomes. This outcome assessment can provide evidence of the clinical utility of the testing and support decisions about whether to continue offering the service.

At a Glance: Biofilm Susceptibility Testing Decision Framework

The following table provides a concise decision framework for laboratory directors evaluating whether and how to implement biofilm susceptibility testing.

Records and Measurements for Biofilm Susceptibility Testing

Essential Data to Record

Laboratories implementing biofilm susceptibility testing should maintain detailed records of all testing activities. These records support quality assurance, troubleshooting, and continuous improvement.

For each testing run, the laboratory should record the date, the testing method, the organisms tested, the antibiotics tested, and the results for each pharmacodynamic parameter measured. The laboratory should also record the quality control results for the run and any deviations from established procedures.

For each isolate tested, the laboratory should record the source of the isolate, the identification results, and the conventional susceptibility testing results. This information provides context for interpreting the biofilm susceptibility results.

Quality Control Records

Quality control records should document the performance of the testing method over time. These records should include the results for quality control organisms, the acceptable ranges for each parameter, and any corrective actions taken when results fell outside the acceptable ranges.

The laboratory should review quality control records regularly to identify trends or patterns that might indicate problems with the testing method. For example, a gradual increase in the minimum biofilm eradication concentration for a quality control organism might indicate a problem with antibiotic preparation or biofilm growth conditions.

Method Validation Records

Method validation records should document the studies performed to establish the performance characteristics of the biofilm susceptibility testing method. These records should include the validation protocol, the results of the validation studies, and the conclusions drawn from the results.

The validation records should also document any changes made to the method after the initial validation and the rationale for those changes. This documentation supports the ongoing validity of the method and provides evidence for regulatory and accreditation purposes.

Outcome Tracking Records

Outcome tracking records should document the clinical outcomes associated with biofilm susceptibility testing. These records should include information about the patient's diagnosis, the treatment selected based on the biofilm susceptibility results, and the clinical response to treatment.

Outcome tracking is challenging because it requires coordination with clinical teams and access to patient data. However, this information is valuable for assessing the clinical utility of biofilm susceptibility testing and for identifying areas where the testing could be improved.

Common Failure Patterns and Troubleshooting

Inconsistent Biofilm Formation

One of the most common problems in biofilm susceptibility testing is inconsistent biofilm formation. Biofilm formation can vary between runs, between wells, and between isolates. This variability can lead to unreliable results and difficulty interpreting the data.

Several factors can contribute to inconsistent biofilm formation. The growth medium, temperature, and incubation time must be carefully controlled. The inoculum density must be standardized, and the surface properties of the test system must be consistent. Some isolates may form biofilms poorly under the test conditions, which can complicate the interpretation of results.

Troubleshooting inconsistent biofilm formation should begin with a review of the testing protocol to ensure that all conditions are controlled. The laboratory should verify that the growth medium is prepared correctly, that the incubator temperature is accurate, and that the inoculum is prepared consistently. If problems persist, the laboratory may need to adjust the growth conditions or select a different testing method.

Carryover of Planktonic Cells

The presence of planktonic cells in the biofilm preparation can confound susceptibility testing results. If planktonic cells are not removed before antibiotic exposure, they may be killed by the antibiotic, leading to an overestimation of the antibiotic's activity against the biofilm.

The washing steps in microtiter plate assays and the Calgary device are designed to remove planktonic cells before antibiotic exposure. However, these washing steps may not be completely effective, particularly if the biofilm is loosely attached or if the washing is not vigorous enough.

To address this problem, the laboratory should verify that the washing steps are effective by examining the biofilm preparations microscopically or by including control wells that are processed without antibiotic exposure. The laboratory should also ensure that the washing protocol is followed consistently.

Incomplete Recovery of Biofilm Cells

The recovery of biofilm cells after antibiotic exposure is a critical step in determining the minimum biofilm eradication concentration. If the recovery is incomplete, the surviving cell count will be underestimated, leading to an overestimation of the antibiotic's activity.

The recovery method must be validated to ensure that it removes all viable cells from the biofilm. Sonication, vortexing, and scraping are commonly used methods, but their effectiveness can vary depending on the organism and the biofilm structure.

The laboratory should validate the recovery method for each organism type tested and should include controls to assess the efficiency of recovery. If recovery is incomplete, the laboratory may need to adjust the recovery method or use a different approach.

Antibiotic Degradation or Inactivation

Antibiotics can degrade or become inactivated under the conditions used for biofilm susceptibility testing. This degradation can lead to an underestimation of the antibiotic's activity and unreliable results.

The stability of antibiotics should be assessed under the test conditions, including the temperature, pH, and duration of exposure. Some antibiotics are more stable than others, and the testing protocol should be designed to minimize degradation.

The laboratory should prepare antibiotic solutions fresh for each testing run and should store them under appropriate conditions. The laboratory should also include quality control organisms with known susceptibility to the antibiotics being tested to monitor for antibiotic degradation.

Interference from the Test System

The test system itself can interfere with antibiotic activity. Some antibiotics may bind to the plastic surfaces of microtiter plates or the pegs of the Calgary device, reducing the effective concentration of the antibiotic. Other antibiotics may be inactivated by components of the growth medium.

The laboratory should assess the potential for interference for each antibiotic tested. This assessment can be performed by comparing the activity of the antibiotic in the test system with its activity in a system without the potentially interfering components.

If interference is detected, the laboratory may need to adjust the testing protocol, select a different test system, or use a different method for measuring antibiotic activity.

Biosafety Considerations for Biofilm Susceptibility Testing

Risk Assessment

Biofilm susceptibility testing involves the manipulation of potentially pathogenic microorganisms. The laboratory must conduct a risk assessment for each organism tested and implement appropriate containment measures based on the biosafety level required.

The Biosafety in Microbiological and Biomedical Laboratories publication from the CDC and NIH provides guidance for risk assessment, containment, and decontamination in microbiological laboratories. The laboratory director should ensure that all personnel are trained in the appropriate biosafety practices and that the laboratory facilities meet the required biosafety level.

Containment and Decontamination

Biofilm susceptibility testing methods involve multiple steps that can generate aerosols or splashes, including pipetting, sonication, and vortexing. These procedures should be performed in a biological safety cabinet to contain any aerosols.

Decontamination of equipment and work surfaces is essential to prevent cross-contamination between tests and to protect laboratory personnel. The laboratory should have written procedures for decontamination and should use appropriate disinfectants that are effective against the organisms being tested.

The effectiveness of disinfectants can be compromised by the presence of biofilms. Research on disinfectant susceptibility of biofilm-forming bacteria has shown that biofilms can reduce the efficacy of disinfectants, and that the choice of disinfectant matters. For example, disinfectants containing peracetic acid and hydrogen peroxide have shown greater efficacy against biofilm-forming Klebsiella pneumoniae isolates compared with disinfectants based on sodium hypochlorite and isopropanol, as reported in Scientific Reports research. The laboratory should select disinfectants that are effective against biofilms and should ensure that decontamination procedures are adequate.

Waste Management

Waste generated during biofilm susceptibility testing, including culture plates, pipette tips, and contaminated materials, must be managed according to applicable regulations and institutional policies. The laboratory should have procedures for the safe disposal of biohazardous waste and should ensure that all personnel are trained in these procedures.

Personnel Training

All personnel involved in biofilm susceptibility testing must receive appropriate training in biosafety practices, including the use of personal protective equipment, the operation of biological safety cabinets, and the procedures for handling spills and exposures. The laboratory should document this training and should provide refresher training on a regular basis.

Quality Control and Assurance

Internal Quality Control

Internal quality control is essential for ensuring the reliability of biofilm susceptibility testing results. The laboratory should establish quality control procedures that monitor the performance of the testing method and detect problems before they affect patient results.

Quality control should include the use of reference strains with known biofilm susceptibility characteristics. These strains should be obtained from authenticated culture collections such as the American Type Culture Collection to ensure their identity and stability.

The laboratory should establish acceptable ranges for quality control results and should take corrective action when results fall outside these ranges. The corrective action should be documented, and the effectiveness of the corrective action should be assessed.

External Quality Assessment

External quality assessment programs provide an independent assessment of the laboratory's performance. These programs involve the testing of unknown specimens and the comparison of results with those of other laboratories.

External quality assessment programs for biofilm susceptibility testing are not widely available, reflecting the lack of standardization in this area. The laboratory director should monitor for the availability of such programs and should participate when possible.

Continuous Quality Improvement

The laboratory should have a process for continuous quality improvement that includes regular review of quality control data, identification of problems, and implementation of corrective actions. This process should involve all personnel involved in biofilm susceptibility testing and should be supported by the laboratory leadership.

The continuous quality improvement process should also include a review of the clinical utility of biofilm susceptibility testing. The laboratory should assess whether the testing is providing useful information to clinicians and whether the results are being used to guide treatment decisions.

Evidence Limitations and Research Gaps

Lack of Standardization

The most significant limitation of biofilm susceptibility testing is the lack of standardization by official agencies. The procedures, parameters, and breakpoints for biofilm susceptibility testing have not been standardized, which limits the comparability of results between laboratories and the interpretation of results in the clinical context, as documented in clinical microbiology research.

Research efforts should be directed to obtaining a deeper understanding of biofilm resistance mechanisms and the evaluation of optimal pharmacokinetic and pharmacodynamic models for biofilm growth. These efforts are needed before biofilm susceptibility testing can be implemented in clinical microbiology laboratories for routine susceptibility testing.

Limited Clinical Outcome Data

The clinical utility of biofilm susceptibility testing has not been established through rigorous clinical studies. While there is a strong rationale for the testing, the evidence that biofilm susceptibility results improve treatment outcomes is limited.

The lack of clinical outcome data makes it difficult for laboratory directors to justify the investment in biofilm susceptibility testing and for clinicians to interpret the results. Prospective studies that evaluate the association between biofilm susceptibility results and treatment outcomes are needed.

Methodological Variability

The various in vitro biofilm models used for susceptibility testing produce different results, reflecting differences in biofilm growth conditions, antibiotic exposure protocols, and endpoint measurements. This methodological variability complicates the comparison of results between studies and the translation of research findings to clinical practice.

The development of standardized methods that produce reproducible results across laboratories is a priority for the field. This standardization will require collaboration between researchers, clinical laboratories, and official agencies.

Organism-Specific Considerations

Biofilm susceptibility testing has been most extensively studied for Pseudomonas aeruginosa in the context of cystic fibrosis. The applicability of the testing to other organisms and clinical conditions is less well established.

Different organisms form biofilms with different structures and physiologies, and their responses to antibiotics may differ. The laboratory director should consider the organism-specific evidence when deciding whether to implement biofilm susceptibility testing and which methods to use.

Professional Escalation Criteria

When to Consult a Reference Laboratory

Laboratories that do not have the technical expertise or resources to implement biofilm susceptibility testing may consider referring requests to a reference laboratory. The laboratory director should identify reference laboratories that offer biofilm susceptibility testing and should establish procedures for referring specimens.

The decision to refer should be based on the clinical need for the testing, the availability of a suitable reference laboratory, and the cost and turnaround time of the referral.

When to Escalate to Infectious Disease Consultation

Biofilm susceptibility testing results should be interpreted in the context of the patient's clinical situation. The laboratory should recommend that clinicians consult with an infectious disease specialist when interpreting biofilm susceptibility results, particularly for complex chronic infections.

The infectious disease specialist can help interpret the results in the context of the patient's history, the pharmacokinetics and pharmacodynamics of the antibiotics being considered, and the available treatment options.

When to Report a Quality or Safety Concern

Laboratory personnel should report any quality or safety concerns related to biofilm susceptibility testing to the laboratory director or the designated quality officer. Concerns may include unexpected quality control results, equipment malfunctions, biosafety incidents, or suspected errors in testing or reporting.

The laboratory should have a process for investigating and documenting these concerns and for implementing corrective actions to prevent recurrence.

Frequently Asked Questions

What is the difference between minimum inhibitory concentration and minimum biofilm eradication concentration?

The minimum inhibitory concentration measures the lowest antibiotic concentration that inhibits visible growth of planktonic bacteria under standardized conditions. The minimum biofilm eradication concentration measures the lowest antibiotic concentration that eradicates a preformed biofilm. The minimum biofilm eradication concentration is typically higher than the minimum inhibitory concentration because biofilm cells are less susceptible to antibiotics than planktonic cells.

Why do conventional susceptibility test results not predict treatment outcomes for chronic infections?

Conventional susceptibility testing measures antibiotic activity against planktonic bacteria, but bacteria in chronic infections often grow as biofilms. Biofilm-growing bacteria exhibit reduced susceptibility to antibiotics through mechanisms such as the extracellular polymeric matrix, physiological heterogeneity, persister cells, and altered gene expression. These differences can produce substantial discrepancies between conventional susceptibility results and clinical outcomes.

What is the Calgary biofilm device?

The Calgary biofilm device is a specialized microtiter plate system with a lid containing 96 pegs on which biofilms grow. The pegs can be transferred to plates containing antibiotic dilutions for exposure, and surviving cells can be recovered for viability assessment. The device is used to determine parameters such as the minimum biofilm eradication concentration.

Can biofilm susceptibility testing be performed directly on clinical specimens?

Some newer microfluidic platforms, such as the BiofilmChip, have demonstrated the ability to attach bacterial cells of clinical origin directly from clinical specimens, as reported in NPJ Biofilms and Microbiomes research. This capability differs from traditional methods that require initial culture of the organism before biofilm susceptibility testing.

Are there standardized breakpoints for biofilm susceptibility testing?

No official agency has yet standardized the procedures, parameters, and breakpoints for biofilm susceptibility testing, according to published research on biofilm susceptibility testing. This lack of standardization means that results cannot be interpreted using established clinical breakpoints and should be considered investigational.

What disinfectants are effective against biofilm-forming bacteria?

Research on biofilm-forming Klebsiella pneumoniae has shown that disinfectants containing peracetic acid and hydrogen peroxide produce larger inhibition zones compared with disinfectants based on sodium hypochlorite and isopropanol, as reported in Scientific Reports research. The presence of biofilms can reduce disinfection efficiency, and the choice of disinfectant matters for effective decontamination.

What biosafety precautions are needed for biofilm susceptibility testing?

Biofilm susceptibility testing involves manipulation of potentially pathogenic microorganisms and should be conducted according to the biosafety level required for the organisms being tested, following guidance from the Biosafety in Microbiological and Biomedical Laboratories publication. Procedures that generate aerosols should be performed in a biological safety cabinet, and decontamination procedures should use disinfectants effective against biofilms.

How should biofilm susceptibility testing results be reported?

Biofilm susceptibility testing results should be reported with a clear description of the testing method and the pharmacodynamic parameters measured. The report should include a statement that interpretive breakpoints have not been established and that results should be interpreted in the context of the patient's clinical situation.

Related Bacteriology Guides

• Chlamydiosis in Birds: Clinical Presentation and Advanced Diagnostic Methods
• Swine Dysentery: Age Susceptibility, Causative Agent, and Clinical Management in Pigs
• Salmonellosis in Poultry: A Comprehensive Clinical Guide
• Common Poultry Diseases: A Clinical Overview
• Avian Mycoplasmosis in Poultry: Clinical Signs and Control

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Antimicrobial susceptibility testing in biofilm-growing bacteria.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2014.
• A new BiofilmChip device for testing biofilm formation and antibiotic susceptibility.. NPJ biofilms and microbiomes, 2021.
• Emerging biofilm formation and disinfectant susceptibility of ESBL-producing Klebsiella pneumoniae.. Scientific reports, 2025.
• Water treatment and monitor disinfection.. Hemodialysis international. International Symposium on Home Hemodialysis, 2006.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.